BioLineRx Ltd (BLRX)

[midastouch017]

On February 13, 2017, BioLineRx Ltd. (the “Company”) received a written notification from The Nasdaq Stock Market (“Nasdaq”) confirming that the Company has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

The Company had previously announced that it had received notice from Nasdaq that the bid price of the Company’s American Depositary Shares (“ADSs”), each representing one ordinary share, was below $1.00 per ADS for the previous 30 consecutive business days and, as a result, the Company was not in compliance with Listing Rule 5550(a)(2) (the “Rule”). The Company was provided with 180 days, or until July 24, 2017, to regain compliance with the Rule. As a result of the Company’s ADSs closing with a bid price of $1.00 per share or greater for at least 10 consecutive business days, Nasdaq informed the Company that it has regained compliance with the minimum bid price requirement and the matter is now closed.